Business
BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\nBioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress\nPR Newswire\nFREDERICK, Md., March 9, 2016\n\n\n\nFREDERICK, Md., March 9, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that a research abstract featuring ActiPatch® will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK  https://www.britishpainsociety.org/2016-asm/.  The Company will also be exhibiting at the Congress: Booth #42.\n\nIan M. Rawe, PhD, BioElectronics Director of Clinical Research will present A Registry Study to Assess the Durability of ActiPatch® - a Novel OTC Neuromodulation Therapy for Chronic Pain. The presentation will show data from over 200 individuals who used ActiPatch for their pain and were monitored for 6 months. The abstract will be published in a supplement to the British Journal of Pain.\n\n\"The data that will be presented represents is an important step forward in our clinical data as we determined durability of ActiPatch® Therapy for 6 months in a large cohort of users,\"  commented Dr. Rawe. \n\nThe majority of the users of ActiPatch®:\n\n\nHad consistent pain relief for the 6 month duration; \nA significant reduction in medication use including opioids and other prescription narcotics; and, \nExperienced substantial improvements in quality of life, sleep and physical activity.\n\"This is a great opportunity to introduce ActiPatch® to the healthcare professionals and researchers with an interest in pain in the UK as ActiPatch® is now widely available over the counter in the UK in the major pharmacy chains including Boots, Lloyds Pharmacy, Super Drug and Gordon's Chemist.\"\n\nAbout BioElectronics CorporationBioElectronics Corporation is a leader in bioelectroceuticals devic...